Effect Of Xinsan On Posterior Circulation Infarct Vertigo

Objective: To investigate the clinical application value of Xinsan on posterior circulation infarct vertigo by observing the improvement effect of DHI scale score,NIHSS scale score,HCY and LDL-C index in patients with posterior circulation infarct vertigo,in order to provide basis for the diagnosis and treatment of posterior circulation infarct vertigo.Methods:A total of 90 patients with posterior circulation infarct vertigo who were hospitalized in the Department of Encephalopathy of Weifang Hospital of Traditional Chinese Medicine from October 2020 to January 2022 were enrolled.All the included cases presented "vertigo/dizziness" as the chief complaint,and the onset time was less than 48 hours,which met the diagnostic criteria of acute ischemic stroke in Chinese Guidelines for the Diagnosis and Treatment of Acute Ischemic Stroke 2018.Brain MRI confirmed that the responsible lesion was located in the blood supply area of the posterior circulation.According to the random number table method,90 patients were divided into 3 groups:control group 1,control group 2 and experimental group,with 30 patients in each group.Control group 1 received conventional basic treatment of western medicine;Control group 2 was treated with jianpi huatan decoction on the basis of control group 1.On the basis of control 2groups,the experimental group added 12 g of Divaricate Saposhnikovia Root,radix angelicae pubescentis and notopterygium root respectively.The treatment course was 4 weeks.Baseline data such as gender,age,risk factors and related biochemical indicators were observed.The changes of DHI scale,NIHSS score scale,LDL-C,Hcy and other indicators were observed to evaluate the therapeutic effect of each group.Results:(1)Baseline comparison: There was no difference in baseline comparison among the three groups(P>0.05).(2)Comparison of DHI scores:After treatment,DHI scores in the three groups decreased(P<0.01),and the experimental group was better than the control group 1(P<0.01)and the control group 2(P<0.05),and the control group2 was better than the control group 1(P<0.05).(3)Comparison of NIHSS scores:After treatment,NIHSS scores of patients in the three groups decreased(P<0.01),the experimental group was better than control group 1(P<0.05),control group 2(P<0.05),there was no difference between control group 2 and control group 1(P>0.05).(4)Comparison of efficacy in lowering HCY:After treatment,the level of HCY in the three groups decreased(P<0.01),and the effect of the experimental group was better than that of the control group 1(P<0.01)and the control group2(P<0.05),and the effect of the control group 2 was better than that of the control group 1(P<0.05).(5)Comparison of LDL-C reduction efficacy:after treatment,LDL-C in the three groups decreased(P<0.01),the effect of the experimental group was better than that of the control group 1(P<0.01),the effect of the control group 2 was better than that of the control group 1(P<0.05),and there was no difference between the experimental group and the control group 2(P>0.05).(6)Safety analysis: There were no obvious adverse reactions in the three groups,indicating good safety.Conclusion:Xinsan therapy can significantly improve the therapeutic effect of posterior circulation infarct vertigo patients,effectively reduce the level of HCY,improve the degree of vertigo in patients,promote the recovery of neurological function,and has clinical application value.